Allison Bratzel
Stock Analyst at Piper Sandler
(4.57)
# 218
Out of 4,868 analysts
39
Total ratings
63.33%
Success rate
22.93%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Allison Bratzel
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| REPL Replimune Group | Maintains: Overweight | $14 → $22 | $9.49 | +131.82% | 2 | Jun 2, 2025 | |
| TYRA Tyra Biosciences | Assumes: Overweight | $33 | $9.50 | +247.37% | 1 | May 21, 2025 | |
| RARE Ultragenyx Pharmaceutical | Maintains: Overweight | $140 → $115 | $37.35 | +207.90% | 1 | Mar 17, 2025 | |
| AKBA Akebia Therapeutics | Maintains: Overweight | $4 → $6 | $3.56 | +68.54% | 1 | Mar 14, 2025 | |
| INZY Inozyme Pharma | Maintains: Overweight | $30 → $23 | $3.99 | +477.16% | 1 | Mar 11, 2025 | |
| ENGN enGene Holdings | Initiates: Overweight | $26 | $3.25 | +700.00% | 1 | Feb 18, 2025 | |
| ARGX argenx SE | Maintains: Overweight | $620 → $725 | $537.92 | +34.78% | 13 | Jan 7, 2025 | |
| TVTX Travere Therapeutics | Maintains: Neutral | $12 → $22 | $14.41 | +52.67% | 2 | Nov 14, 2024 | |
| RIGL Rigel Pharmaceuticals | Maintains: Neutral | $15 → $23 | $19.44 | +18.31% | 2 | Nov 14, 2024 | |
| IONS Ionis Pharmaceuticals | Maintains: Overweight | $65 → $62 | $37.01 | +67.52% | 1 | Nov 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $28 → $42 | $36.32 | +15.64% | 3 | Oct 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $20 → $22 | $11.44 | +92.31% | 2 | Jul 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $4 | $2.36 | +69.49% | 2 | Mar 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $8 → $20 | $4.65 | +330.11% | 4 | Mar 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Overweight | $20 | $3.47 | +476.37% | 1 | Oct 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $100 | $68.27 | +46.48% | 2 | Feb 8, 2023 |
Replimune Group
Jun 2, 2025
Maintains: Overweight
Price Target: $14 → $22
Current: $9.49
Upside: +131.82%
Tyra Biosciences
May 21, 2025
Assumes: Overweight
Price Target: $33
Current: $9.50
Upside: +247.37%
Ultragenyx Pharmaceutical
Mar 17, 2025
Maintains: Overweight
Price Target: $140 → $115
Current: $37.35
Upside: +207.90%
Akebia Therapeutics
Mar 14, 2025
Maintains: Overweight
Price Target: $4 → $6
Current: $3.56
Upside: +68.54%
Inozyme Pharma
Mar 11, 2025
Maintains: Overweight
Price Target: $30 → $23
Current: $3.99
Upside: +477.16%
enGene Holdings
Feb 18, 2025
Initiates: Overweight
Price Target: $26
Current: $3.25
Upside: +700.00%
argenx SE
Jan 7, 2025
Maintains: Overweight
Price Target: $620 → $725
Current: $537.92
Upside: +34.78%
Travere Therapeutics
Nov 14, 2024
Maintains: Neutral
Price Target: $12 → $22
Current: $14.41
Upside: +52.67%
Rigel Pharmaceuticals
Nov 14, 2024
Maintains: Neutral
Price Target: $15 → $23
Current: $19.44
Upside: +18.31%
Ionis Pharmaceuticals
Nov 14, 2024
Maintains: Overweight
Price Target: $65 → $62
Current: $37.01
Upside: +67.52%
Oct 15, 2024
Maintains: Overweight
Price Target: $28 → $42
Current: $36.32
Upside: +15.64%
Jul 10, 2024
Maintains: Overweight
Price Target: $20 → $22
Current: $11.44
Upside: +92.31%
Mar 26, 2024
Maintains: Neutral
Price Target: $4
Current: $2.36
Upside: +69.49%
Mar 14, 2024
Upgrades: Overweight
Price Target: $8 → $20
Current: $4.65
Upside: +330.11%
Oct 13, 2023
Assumes: Overweight
Price Target: $20
Current: $3.47
Upside: +476.37%
Feb 8, 2023
Maintains: Overweight
Price Target: $100
Current: $68.27
Upside: +46.48%